Abizer Gaslightwala, President and CEO of Akari Therapeutics discussed Akari’s commitment to continued research to better understand the multiple effects of its novel spliceosome modulator, PH1Watch the “What This Means” video here BOSTON and LONDON, July 29, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced that Abizer Gaslightwala, President ...